Evidence map›Paper›PMID 40253695›Full record

ArticleCell reports2025

Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma.

Suresh Udutha, Céline Taglang, Georgios Batsios, Anne Marie Gillespie, Meryssa Tran, Johanna Ten Hoeve, Thomas G Graeber, Pavithra Viswanath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suresh UduthaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Céline TaglangDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Georgios BatsiosDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Anne Marie GillespieDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Meryssa TranDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
Johanna Ten HoeveDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, Los Angeles, CA, USA; UCLA Metabolomics Center, Los Angeles, CA, USA.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, Los Angeles, CA, USA; UCLA Metabolomics Center, Los Angeles, CA, USA.
Pavithra ViswanathDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. Electronic address: pavithra.viswanath@ucsf.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
IMAGING TELOMERE MAINTENANCE MECHANISMS IN GLIOMASR01CA239288 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM, VISWANATH, PAVITHRA · 2020 to 2024
$3.2M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA239288
6 · The paper itself

Abstract

Understanding the mechanisms by which oncogenic events alter metabolism will help identify metabolic weaknesses that can be targeted for therapy. Telomerase reverse transcriptase (TERT) is essential for telomere maintenance in most cancers. Here, we show that TERT acts via the transcription factor forkhead box O1 (FOXO1) to upregulate glutamate-cysteine ligase (GCLC), the rate-limiting enzyme for de novo biosynthesis of glutathione (GSH, reduced) in multiple cancer models, including glioblastoma (GBM). Genetic ablation of GCLC or pharmacological inhibition using buthionine sulfoximine (BSO) reduces GSH synthesis from [U-

Indexed as

Brain NeoplasmsGlioblastomaGlutathioneNucleotidesAnimalsButhionine SulfoximineCell Line, TumorGlutamate-Cysteine LigaseGlutamineHumansMiceTelomeraseButhionine SulfoximineGlutamate-Cysteine LigaseGlutamineGlutathioneNucleotidesTelomerasebrain tumorscancerCP: CancerCP: Metabolismglioblastomaglutamine metabolismglutathionein vivo stable isotope tracingmetabolic synthetic lethalitymetabolomicsnucleotide biosynthesistelomerase reverse transcriptaseTERT

Identifiers

PMID40253695
PMCPMC12204606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.